We took part in The New York Times with our vaccination study
We proudly share with you our work that creates value for health.
We took part in The New York Times with our innovative VLP type COVID-19 vaccine study that we started Phase 1 studies in cooperation with TÜBİTAK, METU, and Bilkent University, approved by the Ministry of Health and does not contain genetic material.
We thank all the teams who participated in the study and made us feel this proud.